Ventritex's Bumpy Ride
Executive SummaryVentritex was an early beneficiary of a more responsive FDA, gaining quick approval to label its implantable cardioverter defibrillator with Cardiac Pacemaker’s leads. Its competitors, however, also benefited.
You may also be interested in...
The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.